Stockscreener 앱 받기
4.08
5.15%
0.20
Kalaris Therapeutics Inc 주식(KLRS)의 최신 뉴스
Kalaris Therapeutics Reports Q2 Financial Results, Advances Clinical Program - VisionMonday.com
Kalaris Therapeutics, Inc. 2Q 2026: Net loss $(11.5M), Diluted EPS $(0.48) — 10-Q Summary - TradingView
Kalaris Therapeutics Releases Q2 2026 Financial Results - AlphaStreet
Kalaris Therapeutics Q2 Results: EPS beats estimate, losses narrow 21% YoY - scanx.trade
Kalaris Therapeutics, Inc. (NASDAQ: KLRS) Share Price, KLRS Stock News, KLRS Share Price & Updates - kalkine.ca
Form 8K Kalaris Therapeutics Inc For: 11 August By Investing.com - Investing.com Australia
Kalaris Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Kalaris Therapeutics (NASDAQ:KLRS) Announces Earnings Results - marketbeat.com
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates - The Manila Times
Kalaris Therapeutics Reports Q2 2026 Results and Advances Phase 1b/2 TH103 Study for Neovascular AMD - Quiver Quantitative
Kalaris Reports Q2 2026: $11.5M Quarterly Net Loss; $93.5M Cash on Hand - TradingView
KLRS: TH103 clinical progress and strong cash position support operations into Q4 2027 - TradingView
Kalaris Reports $11.5 Million Q2 Net Loss and TH103 Updates - Quiver Quantitative
BRIEF-Kalaris Therapeutics Inc Q2 Operating Income USD -12.386 Million Vs. IBES Estimate USD -12.5 Million - TradingView
KLRS Stock Price and Chart — NASDAQ:KLRS - TradingView
Kalaris Therapeutics Inc. (KLRS) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Given Average Rating of "Moderate Buy" by Analysts - marketbeat.com
Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4%Here's What Happened - marketbeat.com
KLRS: Abbott Cooper PLLC Announces Investigation on Behalf - GlobeNewswire
Investigation launched into Kalaris Therapeutics board for possible fiduciary breaches since 2024 - pluang.com
Kalaris Therapeutics (KLRS) Holds Gains Near $3.51 as Stock Consolidates Between Key LevelsValue Stock Ideas - dars.gov.et
Kalaris Therapeutics (KLRS) Sees Modest Gain as Stock Holds Above SupportMA Cross Alert - dars.gov.et
Kalaris Therapeutics Inc (KLRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kalaris Therapeutics Inc (KLRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kalaris Therapeutics Inc (KLRS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kalaris Therapeutics Inc (KLRS) Cash Flow - TradingKey
Kalaris Therapeutics Inc (KLRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
TradingKey - TradingKey
KLRS|Kalaris Therapeutics Inc|Price:3.730|Chg%:-0.190 - TradingKey
KLRS|Kalaris Therapeutics Inc|Price:3.830|Chg%:-0.110 - TradingKey
Kalaris Therapeutics Inc (KLRS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kalaris Therapeutics (KLRS) Drops 3.7% as Stock Tests Key Support ZoneEarnings Quality Factor - dars.gov.et
Kalaris appoints Liisa Bayko as CFO - MSN
Why is Kalaris Therapeutics stock gaining Friday? - MSN
Kalaris Therapeutics Appoints Liisa Bayko as New Chief Financial Officer - VisionMonday.com
Kalaris Therapeutics files Form 3 for CFO Liisa Ann Bayko - Bitget
Kalaris Therapeutics appoints Liisa Bayko as CFO By Investing.com - Investing.com Nigeria
Kalaris Therapeutics appoints Liisa Bayko as CFO - Investing.com
Kalaris Therapeutics stock falls despite naming new CFO By Investing.com - Investing.com South Africa
Kalaris Therapeutics Appoints Liisa Bayko as New CFO - Contract Pharma
Kalaris Therapeutics stock falls despite naming new CFO - Investing.com
Kalaris Therapeutics, Inc. Announces Appointment of Liisa Bayko to Chief Financial Officer, Effective July 20, 2026 - marketscreener.com
Kalaris Therapeutics Strengthens Financial Leadership With New CFO - TipRanks
Kalaris Expands Leadership Team Appointing Liisa Bayko as Chief Financial Officer - The Manila Times
After more than two decades in biotech finance, Liisa Bayko joins Kalaris - Stock Titan
Kalaris Therapeutics appoints Liisa Bayko as Chief Financial Officer - scanx.trade
Kalaris Therapeutics Slides Nearly 5% as Support Levels Come into FocusFear Greed Extreme - dars.gov.et
Enterprise value to revenue forward of Kalaris Therapeutics, Inc. – NASDAQ:KLRS - TradingView
KLRS Dips After Intraday Spike Draws Trader Interest - timothysykes.com
Kalaris Therapeutics Shares Rise After More Positive Data From TH103 Trial - Moomoo
KLRS Stock Dips As Traders React To Volatile Intraday Spike - StocksToTrade
KLRS Stock Dips As Traders Weigh Cash Burn And Volatility - timothysykes.com
KLRS Stock Dips As Traders Digest Heavy Intraday Reversal - StocksToTrade
KLRS Stock Dips After Intraday Spike At Key Levels - timothysykes.com
Why Is Kalaris Therapeutics Stock Gaining Friday? - Benzinga
Kalaris Says Additional Patients Show Improved Vision in Phase 1a Trial in Neovascular AMD - Moomoo
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
KLRS Stock Pops As Kalaris Maps Out TH103 Catalysts - StocksToTrade
Kalaris Therapeutics stock surges on positive trial data By Investing.com - Investing.com Australia
Kalaris Therapeutics stock surges on positive trial data - Investing.com
0.52%
0.07%
자본화:
|
볼륨(24시간):